Compare TechnipFMC plc Ordinary Share (FTI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TechnipFMC plc Ordinary Share vs Natera Inc. Common Stock — how do they compare? TechnipFMC plc Ordinary Share trades at $69.36 (market cap $27.73B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× TechnipFMC plc Ordinary Share's market cap, and TechnipFMC plc Ordinary Share pays a 0.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| FTI | NTRA | |
|---|---|---|
Market Cap | $27.73B | $57.03B |
Volume | 2,487,618 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $80.08 | $425.64 |
52-Week Low | $35.57 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $27.98B | $56.18B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTI trades at $70.72, up 1.39% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 36.04% ROE and 11.28% net margin. Recent Petrobras contract wins and strategic hires strengthen its subsea and consulting capabilities. Analyst consensus remains bullish with a $80.50 price target representing 14% upside potential.
FTI presents a compelling growth story with consistent earnings outperformance and strategic expansion, though technical indicators suggest near-term consolidation. The primary risk involves execution of recent contracts and maintaining profitability amid rising expenses. With zero sell ratings and institutional accumulation, the stock offers upside potential for investors comfortable with energy sector volatility.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TechnipFMC plc Ordinary Share
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
